Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG)
Pfisterer J, Dean AP, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Shannon C, Hein A, Reimer DU, Hanker LC, Petit T, Marme F, El-Balat A, Glasspool R, De Gregorio N, Mahner S, Kurtz JE (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Publisher: OXFORD UNIV PRESS
City/Town: OXFORD
Conference Proceedings Title: ANNALS OF ONCOLOGY
Event location: Munich
DOI: 10.1093/annonc/mdy285.142
Authors with CRIS profile
Involved external institutions
Arbeitsgemeinschaft Gynäkologische Onkologie e.V. (AGO)
Germany (DE)
Österreichische Gesellschaft für Gynäkologie und Geburtshilfe - OEGGG
Austria (AT)
Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Australia (AU)
Center François Baclesse
France (FR)
Centre Paul Strauss (UNICANCER)
France (FR)
Hôpitaux universitaires de Strasbourg (HUS) / University Hospital Strasbourg
France (FR)
Germany (DE)
Österreichische Gesellschaft für Gynäkologie und Geburtshilfe - OEGGG
Austria (AT)
Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Australia (AU)
Center François Baclesse
France (FR)
Centre Paul Strauss (UNICANCER)
France (FR)
Hôpitaux universitaires de Strasbourg (HUS) / University Hospital Strasbourg
France (FR)
How to cite
APA:
Pfisterer, J., Dean, A.P., Baumann, K., Rau, J., Harter, P., Joly, F.,... Kurtz, J.-E. (2018). Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
MLA:
Pfisterer, J., et al. "Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG)." Proceedings of the 43rd ESMO Congress (ESMO), Munich OXFORD: OXFORD UNIV PRESS, 2018.
BibTeX: Download